What it sells
Multimodal foundation models to predict uncollected patient biology
Business model breakdown
Buyer: who owns the budget?
UnverifiedHeads of translational medicine / pathology / biomarker R&D at pharma and biotech.
Trigger: what makes them buy now?
Multiplex immunofluorescence is expensive, slow and consumes scarce tissue while trial biopsy requirements tighten.
Workflow: what inputs become what output?
Send existing H&E slides; Lattice predicts spatially resolved protein-marker maps as virtual mIF channels across an archive; optionally fine-tuned to the customer's indications and marker panel.
Economics: what it saves and how it charges
UnverifiedProject-based/model access replacing wet-lab mIF assays with computation; no price figures.
Distribution: how it reaches customers
Enterprise sales: work-email "Discuss your project" form, plus web app and docs/developers.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.